# A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

> **NCT02834247** · PHASE1 · TERMINATED · sponsor: **Calithera Biosciences, Inc** · enrollment: 41 (actual)

## Conditions studied

- Triple-Negative Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Head and Neck Carcinoma, Squamous Cell
- Advanced Solid Tumors

## Interventions

- **DRUG:** TAK-659
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02834247
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-12
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Insufficient efficacy of drug; no safety concern
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834247, "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02834247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*